Faruqi and Faruqui, LLP Logo
Share this page

Sunesis Pharmaceuticals Inc. (SNSS)



Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Sunesis Pharmaceuticals Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Sunesis Pharmaceuticals Inc. (“Sunesis” or the “Company”) (NASDAQ:SNSS).

The investigation focuses on whether the Company and its executives violated federal securities laws by failing to appropriately disclose the suitability of the Company’s treatment for elapsed/refractory acute myeloid leukemia (“AML”), vosaroxin, to receive approval in Europe.

Specifically, on May 2, 2017, Sunesis announced that the Company will withdraw its European Marketing Authorization Application for vosaroxin, following recent interactions with the European Medicine Agency's Committee for Medicinal Products for Human Use. The Company announced that it had learned that the committee was likely to formally adopt a negative opinion in its evaluation of the product, leading to its withdrawal.

On this news, Sunesis’s share price fell from $3.66 per share on May 1, 2017 to a closing price of $2.96 on May 2, 2017—a $0.70 or a 19% drop.

If you invested in Sunesis stock or options and would like to discuss your legal rights, please fill out the form below.  You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com.

Request Information

Please tell us about yourself by completing the form and we will provide you with additional
information on how to join the Class Action at no cost to you.

  • Case:
    Sunesis Pharmaceuticals Inc. (SNSS)

* The submission of this form does not create an attorney-client relationship.

Contact Counsel

Richard W. Gonnello
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330


Case Details


  • 05/02/2017

Send Information

If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.